Jiangsu (SH:688426)2025-01-15 10:37Financial Performance - The company expects a net loss attributable to shareholders of between -142 million to -170 million yuan for 2024, representing a decline of 68.23% to 101.40% compared to the previous year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -166 million to -194 million yuan, a decrease of 38.92% to 62.35% year-over-year[2]. - The previous year's net profit attributable to shareholders was -84.41 million yuan, with a total profit of -92.98 million yuan[3]. - The decline in net profit is primarily due to a decrease in revenue from core business operations, despite an increase in sales volume and customer numbers[4]. Investment and R&D - The company is investing heavily in R&D, particularly in the fields of fourth-generation sequencing, gene synthesis, and diagnostics, to maintain its technological edge[5]. - Increased sales expenses are noted as the company expands its marketing efforts to enhance market share and customer satisfaction[5]. Earnings Forecast and Risks - The company has not identified any significant uncertainties that would affect the accuracy of the earnings forecast[6]. - The earnings forecast is based on preliminary calculations and has not yet been audited by a registered accountant[6]. - Investors are advised to pay attention to investment risks as the data provided is subject to change pending the official annual report[7].